Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …
Background Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …
GV Scagliotti, R Gaafar, AK Nowak… - The Lancet …, 2019 - europepmc.org
Background Nintedanib targets VEGF receptors 1-3, PDGF receptors α and β, FGF receptors
1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma …
1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma …
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …
GV Scagliotti, R Gaafar, AK Nowak… - The lancet …, 2019 - repository.uantwerpen.be
Background Nintedanib targets VEGF receptors 1-3, PDGF receptors alpha and beta, FGF
receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural …
receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural …
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …
GV Scagliotti, R Gaafar, AK Nowak, T Nakano… - The Lancet Respiratory …, 2019 - Elsevier
Background Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …
GV Scagliotti, R Gaafar, AK Nowak… - The Lancet …, 2019 - research.regionh.dk
BACKGROUND: Nintedanib targets VEGF receptors 1-3, PDGF receptors α and β, FGF
receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural …
receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural …
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …
GV Scagliotti, R Gaafar… - Lancet …, 2019 - research-repository.uwa.edu.au
Background Nintedanib targets VEGF receptors 1-3, PDGF receptors alpha and beta, FGF
receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural …
receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural …
[PDF][PDF] Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a …
GV Scagliotti, R Gaafar, AK Nowak, T Nakano… - …, 2019 - medialibrary.uantwerpen.be
Background Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …
GV Scagliotti, R Gaafar, AK Nowak… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Nintedanib targets VEGF receptors 1-3, PDGF receptors α and β, FGF receptors
1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma …
1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma …
[引用][C] Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a …
GV Scagliotti, R Gaafar, AK Nowak, T Nakano… - THE LANCET …, 2019 - iris.unito.it
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …
GV Scagliotti, R Gaafar… - The Lancet …, 2019 - mdanderson.elsevierpure.com
Background: Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …